Last Posted: May 19, 2022
- Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma.
Madanat-Harjuoja Laura M et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 OF1-OF8
- Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Caputo Vincenza et al. Therapeutic advances in medical oncology 2022 1417588359221096878
- Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel.
Ryan Daniel J et al. Lung cancer (Amsterdam, Netherlands) 2022 16867-73
- Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M et al. ESMO open 2022 7(3) 100481
- A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa "(AI-REAL)".
Legason Ismail D et al. BMC cancer 2022 22(1) 484
- ENPP2 Promoter Methylation Correlates with Decreased Gene Expression in Breast Cancer: Implementation as a Liquid Biopsy Biomarker.
Panagopoulou Maria et al. International journal of molecular sciences 2022 23(7)
- Can cancer blood tests live up to promise of saving lives?
CK Johnson, AP News, April 11, 2022
- CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
Prabhash Kumar et al. Indian journal of cancer 2022 59(Supplement) S11-S18
- Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer.
Gouton Etienne et al. Current oncology (Toronto, Ont.) 2022 29(3) 1902-1918
- Obstacles to Covering Precision Medicine Multicancer Screenings- Multicancer screening tests are a form of precision medicine that may reduce low value spending, but payers face a number of challenges in deciding whether to cover them.
K Wadill, Health Payer Intelligence, March 2022
Search Result Summary
- CDC Information (0)
- NIH Information (7)
- CDC Publications (0)
- COVID-19 (4)
- Human Genome Epidemiologic Studies (130)
- GWAS Studies (0)
- Human Genomics Translation/Implementation Studies (120)
- Genomic Tests Evidence Synthesis (3)
- Genomic Tests Guidelines (9)
- Tier-Classified Guidelines (2)
- Non-Genomics Precision Health (2)
- Pathogen Advanced Molecular Detection (2)
- State Public Health Genomics Programs (0)
- Ethical/Legal and Social Issues (ELSI) (0)
Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.